Open Market Insiders Trades - Sells only
This list includes insiders general transaction with codes filed in Form 4 from SEC:
- S - Open market or private sale of non-derivative or derivative security
- V - Transaction voluntarily reported earlier than required
| Ticker | Insider | Transaction Type | Ownership Type | Shares Traded | Value / Price | Filing Date |
|---|---|---|---|---|---|---|
|
EVBG
|
Gary R. Phillips
SVP, Sales |
SELL
Open market or private sale
|
Direct | 6,367 Reduced 85.9% |
$151,917
$23.86 p/Share
|
Jun 12
2017 |
|
EVBG
|
W. Putra Cintawati |
SELL
Open market or private sale
|
Indirect | 5,650 Reduced 1.58% |
$134,696
$23.84 p/Share
|
Jun 12
2017 |
|
NP
|
Julie Schertell
President and CEO |
SELL
Open market or private sale
|
Direct | 1,219 Reduced 26.44% |
$98,312
$80.65 p/Share
|
Jun 12
2017 |
|
NP
|
Bonnie Cruickshank Lind
SVP, CFO & Treasurer |
SELL
Open market or private sale
|
Direct | 1,500 Reduced 37.32% |
$121,500
$81.0 p/Share
|
Jun 12
2017 |
|
EVBG
|
Hawkins Nicholas S. A.
Managing Director, EMEA |
SELL
Open market or private sale
|
Direct | 5,683 Reduced 100.0% |
$135,426
$23.83 p/Share
|
Jun 12
2017 |
|
NVDA
|
Tench Coxe
Director |
SELL
Open market or private sale
|
Indirect | 50,000 Reduced 4.22% |
$8,226,500
$164.53 p/Share
|
Jun 09
2017 |
|
LLY
|
Michael J Harrington
Senior VP and General Counsel |
SELL
Open market or private sale
|
Direct | 22,833 Reduced 26.9% |
$1,825,955
$79.97 p/Share
|
Jun 09
2017 |
|
IDCC
|
Robert S Roath
Director |
SELL
Open market or private sale
|
Direct | 800 Reduced 4.96% |
$67,512
$84.39 p/Share
|
Jun 09
2017 |
|
IDCC
|
Jean F Rankin
Director |
SELL
Open market or private sale
|
Direct | 950 Reduced 5.07% |
$80,132
$84.35 p/Share
|
Jun 09
2017 |
|
IDCC
|
John D. Markley Jr.
Director |
SELL
Open market or private sale
|
Direct | 450 Reduced 14.4% |
$37,971
$84.38 p/Share
|
Jun 09
2017 |
|
IDCC
|
John A Kritzmacher
Director |
SELL
Open market or private sale
|
Direct | 1,075 Reduced 9.64% |
$90,708
$84.38 p/Share
|
Jun 09
2017 |
|
IDCC
|
Jeffrey K Belk
Director |
SELL
Open market or private sale
|
Direct | 800 Reduced 4.49% |
$67,512
$84.39 p/Share
|
Jun 09
2017 |
|
CRSP
|
Rodger Novak
President |
SELL
Open market or private sale
|
Direct | 1,100 Reduced 0.09% |
$16,588
$15.08 p/Share
|
Jun 09
2017 |
|
AMKR
|
Stephen Douglas Kelley
President and CEO |
SELL
Open market or private sale
|
Direct | 32,924 Reduced 14.02% |
$397,063
$12.06 p/Share
|
Jun 09
2017 |
|
SFNC
|
Christopher R Kirkland
Director |
SELL
Open market or private sale
|
Indirect | 4,246 Reduced 1.2% |
$233,530
$55.0 p/Share
|
Jun 09
2017 |
|
SFNC
|
Christopher R Kirkland
Director |
SELL
Open market or private sale
|
Direct | 2,363 Reduced 0.98% |
$129,965
$55.0 p/Share
|
Jun 09
2017 |
|
SFNC
|
Joseph D Porter
Director |
SELL
Open market or private sale
|
Direct | 10,721 Reduced 18.01% |
$589,655
$55.0 p/Share
|
Jun 09
2017 |
|
TZOO
|
Ralph Bartel
> 10% Shareholder |
SELL
Open market or private sale
|
Indirect | 2,500 Reduced 0.03% |
$26,950
$10.78 p/Share
|
Jun 09
2017 |
|
AMKR
|
Roger Anthony Carolin
Director |
SELL
Open market or private sale
|
Direct | 10,000 Reduced 25.33% |
$120,500
$12.05 p/Share
|
Jun 08
2017 |
|
ABT
|
Stephen R Fussell
Executive Vice President |
SELL
Open market or private sale
|
Direct | 196,550 Reduced 51.9% |
$9,088,472
$46.24 p/Share
|
Jun 08
2017 |
|
CRSP
|
Rodger Novak
President |
SELL
Open market or private sale
|
Direct | 4,203 Reduced 0.34% |
$63,045
$15.0 p/Share
|
Jun 08
2017 |
|
AMKR
|
Stephen Douglas Kelley
President and CEO |
SELL
Open market or private sale
|
Direct | 75,586 Reduced 24.35% |
$916,858
$12.13 p/Share
|
Jun 08
2017 |
|
RARX
|
Novartis Bioventures LTD
> 10% Shareholder |
SELL
Open market or private sale
|
Direct | 700 Reduced 0.03% |
$15,400
$22.0 p/Share
|
Jun 08
2017 |
|
PK
|
Blackstone Real Estate Associates Vi L.P.
> 10% Shareholder |
SELL
Open market or private sale
|
Indirect | 15,000,000 Reduced 46.85% |
$390,749,989
$26.05 p/Share
|
Jun 07
2017 |
|
COST
|
James P. Murphy
Executive VP |
SELL
Open market or private sale
|
Direct | 5,000 Reduced 9.29% |
$906,500
$181.3 p/Share
|
Jun 07
2017 |
|
RARX
|
Novartis Bioventures LTD
> 10% Shareholder |
SELL
Open market or private sale
|
Direct | 4,840 Reduced 0.21% |
$107,012
$22.11 p/Share
|
Jun 07
2017 |
|
ADI
|
James Champy
Director |
SELL
Open market or private sale
|
Direct | 81 Reduced 0.53% |
$6,538
$80.72 p/Share
|
Jun 07
2017 |
|
UNH
|
William C Ballard Jr
Director |
SELL
Open market or private sale
|
Direct | 5,000 Reduced 6.6% |
$913,200
$182.64 p/Share
|
Jun 07
2017 |
|
AAPL
|
Daniel J. Riccio
Senior Vice President |
SELL
Open market or private sale
|
Direct | 11,949 Reduced 50.0% |
$1,858,070
$155.5 p/Share
|
Jun 07
2017 |
|
ACU
|
Brian S Olschan
President and COO |
SELL
Open market or private sale
|
Direct | 99 Reduced 0.25% |
$2,772
$28.0 p/Share
|
Jun 07
2017 |
|
COST
|
Daniel M. Hines |
SELL
Open market or private sale
|
Direct | 5,000 Reduced 14.8% |
$906,600
$181.32 p/Share
|
Jun 06
2017 |
|
ACU
|
Brian S Olschan
President and COO |
SELL
Open market or private sale
|
Direct | 2,323 Reduced 5.54% |
$65,044
$28.0 p/Share
|
Jun 06
2017 |
|
NEM
|
William N Mac Gowan
EVP, Human Resources |
SELL
Open market or private sale
|
Direct | 2,006 Reduced 1.53% |
$70,210
$35.0 p/Share
|
Jun 06
2017 |
|
NEM
|
E Randall Engel
EVP, Strategic Development |
SELL
Open market or private sale
|
Direct | 5,700 Reduced 2.17% |
$199,500
$35.0 p/Share
|
Jun 06
2017 |
|
RARX
|
Novartis Bioventures LTD
> 10% Shareholder |
SELL
Open market or private sale
|
Direct | 7,274 Reduced 0.31% |
$167,157
$22.98 p/Share
|
Jun 06
2017 |
|
HBNC
|
James D Neff
President |
SELL
Open market or private sale
|
Direct | 2,829 Reduced 1.88% |
$92,197
$32.59 p/Share
|
Jun 06
2017 |
|
NP
|
Larry Newton Brownlee
VP & Controller |
SELL
Open market or private sale
|
Direct | 1,450 Reduced 43.13% |
$115,666
$79.77 p/Share
|
Jun 05
2017 |
|
COST
|
John D Mc Kay
Executive Vice President |
SELL
Open market or private sale
|
Direct | 3,000 Reduced 4.57% |
$544,800
$181.6 p/Share
|
Jun 05
2017 |
|
RARX
|
Novartis Bioventures LTD
> 10% Shareholder |
SELL
Open market or private sale
|
Direct | 4,780 Reduced 0.21% |
$110,466
$23.11 p/Share
|
Jun 05
2017 |
|
PLXS
|
Dean A Foate
Director |
SELL
Open market or private sale
|
Direct | 5,000 Reduced 2.02% |
$266,650
$53.33 p/Share
|
Jun 05
2017 |
|
TMO
|
Stephen Williamson
Sr. VP and CFO |
SELL
Open market or private sale
|
Direct | 2,500 Reduced 6.21% |
$440,650
$176.26 p/Share
|
Jun 05
2017 |
|
UPS
|
Kathleen M. Gutmann
Pres Intl, Healthcare and SCS |
SELL
Open market or private sale
|
Direct | 2,000 Reduced 100.0% |
$214,980
$107.49 p/Share
|
Jun 05
2017 |
|
SQ
|
James Morgan Mc Kelvey Jr.
Director |
SELL
Open market or private sale
|
Direct | 90,000 Reduced 48.31% |
$2,102,400
$23.36 p/Share
|
Jun 05
2017 |
|
BX
|
Joan Solotar
SMD, Head of Global PWS |
SELL
Open market or private sale
|
Direct | 30,500 Reduced 16.87% |
$1,015,955
$33.31 p/Share
|
Jun 05
2017 |
|
ACU
|
Brian S Olschan
President and COO |
SELL
Open market or private sale
|
Direct | 687 Reduced 1.71% |
$19,442
$28.3 p/Share
|
Jun 05
2017 |
|
SPOK
|
Vincent D Kelly
President & CEO |
SELL
Open market or private sale
|
Indirect | 5,000 Reduced 1.4% |
$89,200
$17.84 p/Share
|
Jun 02
2017 |
|
UNH
|
Gail R Wilensky |
SELL
Open market or private sale
|
Direct | 5,540 Reduced 9.07% |
$990,275
$178.75 p/Share
|
Jun 02
2017 |
|
AAPL
|
Luca Maestri
Senior Vice President, CFO |
SELL
Open market or private sale
|
Direct | 4,757 Reduced 87.86% |
$735,527
$154.62 p/Share
|
Jun 02
2017 |
|
RARX
|
Novartis Bioventures LTD
> 10% Shareholder |
SELL
Open market or private sale
|
Direct | 14,867 Reduced 0.64% |
$348,928
$23.47 p/Share
|
Jun 02
2017 |
|
RARX
|
Novartis Bioventures LTD
> 10% Shareholder |
SELL
Open market or private sale
|
Direct | 10,722 Reduced 0.46% |
$256,149
$23.89 p/Share
|
Jun 01
2017 |